Health

Merck to seek authorization for oral Covid drug

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo

WASHINGTON: Pharmaceutical company Merck said Friday it will seek authorization in the US for an oral drug for Covid-19, after the pill showed "compelling results" in a clinical trial.

The experimental drug, molnupiravir, significantly reduced the risk of hospitalization or death when administered to high-risk patients early in the disease, Merck and its partner Ridgeback Biotherapeutics said in a statement.

"At the interim analysis, 7.3 percent of patients who received molnupiravir were hospitalized through Day 29, compared with 14.1 percent of placebo-treated patients who were hospitalized or died."

The phase three clinical trial evaluated data from 775 patients with laboratory-confirmed mild to moderate Covid.

"Merck plans to seek emergency use authorization in the US as soon as possible and to submit applications to regulatory agencies worldwide," the companies said.

Molnupiravir, one of several oral pills for Covid being developed, is meant to stop the virus from replicating.

 

Recommended





Advertisement

Comments

Your feedback is important to us!

We invite all our readers to share with us their views and comments about this article.

Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.

Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)

comments powered by Disqus

Advertisement

FOLLOW THIS ARTICLE

Interested in knowing more about this story?

Click here